996 related articles for article (PubMed ID: 25238659)
1. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
Yıldız GA; Şükür YE; Ateş C; Aytaç R
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
[TBL] [Abstract][Full Text] [Related]
2. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
4. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
5. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
[TBL] [Abstract][Full Text] [Related]
6. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial.
Serna J; Cholquevilque JL; Cela V; Martínez-Salazar J; Requena A; Garcia-Velasco JA
Fertil Steril; 2008 Dec; 90(6):2190-5. PubMed ID: 18191847
[TBL] [Abstract][Full Text] [Related]
7. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
8. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
[TBL] [Abstract][Full Text] [Related]
10. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
11. Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.
Ozmen B; Sükür YE; Seval MM; Ateş C; Atabekoğlu CS; Sönmezer M; Berker B
Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():137-40. PubMed ID: 25461367
[TBL] [Abstract][Full Text] [Related]
12. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
13. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
[TBL] [Abstract][Full Text] [Related]
16. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection.
Isikoglu M; Ozgur K; Oehninger S
J Reprod Med; 2007 Jul; 52(7):639-44. PubMed ID: 17847764
[TBL] [Abstract][Full Text] [Related]
17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pregnancy outcomes of progesterone or progesterone + estradiol for luteal phase support in ICSI-ET cycles.
Gorkemli H; Ak D; Akyurek C; Aktan M; Duman S
Gynecol Obstet Invest; 2004; 58(3):140-4. PubMed ID: 15205566
[TBL] [Abstract][Full Text] [Related]
19. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.
Aboulghar MA; Marie H; Amin YM; Aboulghar MM; Nasr A; Serour GI; Mansour RT
Reprod Biomed Online; 2015 Jan; 30(1):52-6. PubMed ID: 25456166
[TBL] [Abstract][Full Text] [Related]
20. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]